You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (34) |
Back to Search
EFFECTIVENESS AND SAFETY OF NIVOLUMAB IN SQUAMOUS CELL CANCER OF THE HEAD AND NECK´S PATIENTS
- At: Virtual 2020 (2020)
- Type: Poster
- Poster code: POS-HPS-009
- By: CANO DOMíNGUEZ, Sergio (Hospital Universitario Virgen de las Nieves, Hospital pharmacy, Spain)
- Co-author(s): Sergio Cano Domínguez: Hospital pharmacy, Hospital Universitario Virgen de las Nieves, Granada, Spain
Eduardo Tejedor Tejada: Hospital pharmacy, Hospital Universitario Torrecárdenas, Almería, Spain
María José Gándara Ladrón de Guevara: Hospital pharmacy, Hospital Universitario Virgen de las Nieves, Granada, Spain - Abstract:
Background
Nivolumab is a PD1 receptor inhibitor indicated for the treatment of patients with head and neck squamous cell carcinoma (HNSCC).Purpose
Assess effectiveness and safety of nivolumab in monotherapy in recurrent or metastatic HNSCC who progresses during or after platinum-based treatment.
Methods
Retrospective observational multicenter.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026